AvroBio   Report issue

For profit Phase 2
Founded: Cambridge MA United States (2015)

Organization Overview

First Clinical Trial
2018
NCT03454893
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

AvroBio

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fabry Disease (Phase 2)

Gaucher Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3